Concert: Phase 3 data show Deuruxolitinib significantly improve scalp hair regrowth in Alopecia Areata
The Phase 3 data presented at AAD include a comprehensive review of the THRIVE-AA2 results and further elaborate the topline data reported in August 2022
Read full article »
Concert is a Massachusetts-based biopharmaceutical company that researches and develops small-molecule drugs for the treatment of autoimmune diseases.
Read more